

October 4, 2005

AnGes MG, Inc.

Medical -Use Patent for HGF (VEGF) Gene Granted in the U.S.
- Covering Cerebrovascular Disorders -

AnGes MG announces that its medical-use patent for HGF (or VEGF) gene for cerebrovascular disorders has been granted in the U.S., with the U.S. official patent gazette (U.S. 6,936,594) published.

The present invention features the introduction of HGF (or VEGF) gene encapsulated within HVJ liposome into the subarachnoid cavity that provides new therapeutic and preventive measures for cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, cerebral apoplexy, cerebral hemorrhage, moyamoya disease, cerebrovascular dementia, senile dementia and the aftereffects of cerebral hemorrhage or cerebral infarction.

Currently, no effective treatment to restore blood flow decreased by cerebrovascular disorders has been established yet, so that the present invention, which helps induce neoangiogenesis in the periphery of cerebral ischemic lesions, is expected to contribute a great deal to recovery from such diseases and in the prevention of attacks.

AnGes MG has already been clinically developing HGF gene for peripheral arterial disease (PAD) and ischemic heart disease (IHD) both in Japan and the U.S.

This development is planned to lead application of the HGF gene to cranial nerves, so the present invention constitutes the core of such future application of HGF gene therapy along with a medical use of the HGF gene for Parkinson's disease.

AnGes MG plans to further expand the application of the HGF gene by establishing treatments for targets such as myocardiopathy, dermatosis and hearing impairment, and has globally filed patent applications on such treatments.

AnGes MG is determined to continue its proactive promotion of preclinical and clinical development with the intention of expanding the application of HGF gene more widely, while also making efforts to establish related intellectual property rights.